Marisa Wexler, MS,  senior science writer—

A trio of scientists is being honored for research contributions that helped lead to the development of Trikafta, a triple-drug combination medication for people with cystic fibrosis (CF). The three winners of this year’s Lasker~DeBakey Clinical Medical Research Award are Paul Negulescu, PhD, senior vice president at Vertex…

The Cystic Fibrosis Foundation is investing up to €6.5 million (about $7.6 million) to support the development of virus-based therapies to treat Pseudomonas infections in people with cystic fibrosis (CF). The funding to Snipr Biome — which plans to use gene editing technology to improve the viruses’ ability…

SPL84, an investigational inhalation therapy designed to treat cystic fibrosis (CF) caused by a specific mutation called 3849+10 kb C-to-T, was well tolerated in a Phase 2 clinical trial. Trial data also suggest that most CF patients treated with SPL84 experienced improvements in a measure of lung function, according…

The first participants have been dosed in a clinical trial that’s testing some of Sionna Therapeutics’ investigational treatments for cystic fibrosis (CF). The Phase 1 study (NCT07035990) is testing SION-451 with either SION-2222 or SION-109 in healthy volunteers, with the main goal being to evaluate the safety…

The U.S. Food and Drug Administration (FDA) has granted two new designations to CMTX-101, an antibody-based therapy Clarametyx Biosciences is developing to treat bacterial lung infections in people with cystic fibrosis (CF). The regulatory agency granted CMTX-101 fast track designation, which aims to speed the development of new…

Grants that provide financial assistance for nutrition may help people with cystic fibrosis (CF) maintain a healthy body weight, according to a study whose findings emphasize clinicians’ role in making sure patients know about the resources available to them. “The results of our study highlight the importance of active…

Men with cystic fibrosis (CF) are generally knowledgeable about how their disease affects fertility, but they still want to be able to talk about their reproductive options with their providers, who may be uncomfortable or unskilled with these discussions, particularly with teens.. The findings indicate a need for more…

Health Canada has approved the next-generation CFTR modulator therapy Alyftrek for people 6 years and older with cystic fibrosis (CF) who have at least one mutation that’s responsive to the therapy. That includes the most common CF-causing mutation, F508del. The approval in Canada follows similar approvals in…

A lack of stability in a specific region of the CFTR protein may explain why certain people with cystic fibrosis (CF) don’t respond to available modulator therapies, a new study suggests. The findings imply drugs to stabilize this specific region — some of which are already in clinical development…

Two experimental CFTR modulator therapies being developed by Sionna Therapeutics are able to improve the function of the most common mutated form of CFTR protein that causes cystic fibrosis (CF). That’s according to new data Sionna presented at the European Cystic Fibrosis Society (ECFS) 48th European Cystic Fibrosis…